Traditional Chinese Medicine
- 942.089
- -19.302-2.01%
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Historically the most 'competitive'? The Tenth Batch of National Procurement Pharmaceutical Catalog Is Officially Announced with one type having up to 31 companies competing.
①This afternoon, the National Pharmaceutical Joint Procurement Office officially announced the tenth batch of nationally purchased pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Several industry insiders have stated that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A document of the tenth batch of national procurement reporting catalog has circulated within the industry. Today, when the reporter verified with the relevant department, they indicated that it is an internal document not for public release, and the formal joint procurement document will be released publicly later. ②Several industry experts have provided feedback to the reporter, stating that this reporting catalog does not represent the final procurement catalog. However, the competitive landscape of the tenth batch of national procurement will involve at least seven companies. ③The competition for the tenth batch of national procurement will be exceptionally fierce.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.
Tong Ren Tang Technologies Co. Ltd. Non-GAAP EPS of C$0.43, Revenue of C$23.89M
Kenbei Miao (02161.HK) cancelled 3.662 million shares and repurchased shares on February 27
On February 27, Gelonghui | Jianbei Miaomiao (02161.HK) issued an announcement to cancel 3.662 million shares purchased on February 27, 2024.
E-Home Household Services Subsidiary Provides Business Plan and Partners With Traditional Chinese Medicine Company
Express News | National Health Commission: carry out TCM intervention activities in adolescent myopia, obesity and scoliosis
China Resources Pharma Concludes Purchase of Controlling Stake in Boya Bio
China Healthwise Unit Divests 6 Million Shares in IDG Energy
Wai Yuen Tong Medicine Turns to Profit in Fiscal H1 on Higher Revenue; Shares Jump 4%
TOT Biopharm International Forms Pharma Sales JV With China Resources Pharmaceutical
Luye Pharma Submits Investigational New Drug Application for Parkinson's Disease Treatment to US FDA
Luye Pharma Grants Swiss Partner Exclusive Rights for Dementia Treatment in Switzerland
Wai Yuen Tong Medicine to Turn to Profit in Fiscal H1; Shares surged about 18%
China Healthwise Unit Offloads Shares in IDG Energy Investment
Shineway Pharma's January-September Revenue Rises 24%
JBM Healthcare Projects Profit Drop in Fiscal H1